Lucid Diagnostics Inc (LUCD) Stock Price, Quote & News

Company Profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths th...

Industry: Medical Devices

Sector: Healthcare

Phone: 917 813 1828

Website: www.luciddx.com

Address:

360 Madison Avenue, 25th Floor, New York, United States

dmc4321 Jan. 14 at 2:52 AM

$LUCD Its an Oaksapollo post but he is getting LAZY so he is recycling his previously proven wrong lies. LUCD WILL BE (not might be, not could be) in Breech of the major Covenant of their 2024 November Financing on 24th of May of 2026. The Note Holder in September 2025 already appointed a RESTRUCTURING specialist, John Palumbo, so you are watching a train crash about to happen. but you have a choice. Be a passenger on the train and suffer the consequences or dont get on and just watch.

0 · Reply

DrKyle Jan. 14 at 1:00 AM

$LUCD hello friends, few months ago I mention $LPCN to you...THE RIDE in not over for Lipocine as the market cap is still a laughable 60m with a float of roughly 5.5m shares, but Lucid is absolutely next to break out! Any day now...most likely this Thursday the ride begins. Buckle up!

1 · Reply

oaksapollo Jan. 13 at 6:12 PM

$LUCD The unique thing about this LCD catalyst is that it's not the end, only the beginning. Once a draft coverage LCD exists, many other insurers will follow suit and begin covering EsoGuard. It will be like 1 domino setting off a sea of dominoes. Again, coverage is the only thing lacking here. KOLs have stated this on the record. Once coverage is in place, every GI practice in the country as well as may GPs and hospital systems will adopt EsoGuard testing and test volume will explode.

1 · Reply

SamGantVHee Jan. 13 at 5:08 PM

$LUCD I like this quiet period...

0 · Reply

oaksapollo Jan. 12 at 9:51 PM

$LUCD lowest volume since Jan 2025.

2 · Reply

oaksapollo Jan. 12 at 4:01 PM

$LUCD Very happy today that my largest position (LUCD) is FDA-independent. Feel bad for Atara and all the other small companies like them who are just trying to bring important therapies to market. Meanwhile FDA is playing a shell game. If their word can no longer be trusted, how can any biotech/pharma operate efficiently and effectively? This is not good. https://investors.atarabio.com/news-events/press-releases/detail/380/atara-biotherapeutics-provides-regulatory-and-business

1 · Reply

dmc4321 Jan. 12 at 2:57 AM

So you have no issue with my interpretation based on the FACTS. its Funny the supposedly 10X Engineer CryptoBiobitch😇is the only one of the Twitter PUMPERS that has come back. There used to be 10's of posts / cross posts / retweeting around February / March of last year. Now? SILENCE. UTTER Silence. I believe, and I could be wrong, that a goodly number of possible retail investors, particualry the ones that have sizeable portfolios, have seen my god awful long responses, investigated the facts I have put forward and said "No way" and just disappeared as $LUCD is not "investable" That is my goal, so I feel I am collecting my precious KARMA. If I was invested I would be demanding from Dennis the EXACT wording of the Covenant. It looks like there is no wiggle room in it, but MAYBE, just MAYBE, there is. A draft is a document which is supposed to be changed hence "draft". So that will not meet the CMS approval requirement that has to be breeched on May 22 of 2026.

1 · Reply

oaksapollo Jan. 11 at 8:39 PM

$LUCD Cologuard is sponsoring the NFL wild card game. Pretty cool to see a cancer screening test go so mainstream. Someday Freddy, someday…

2 · Reply

Lets_Go_Brndn Jan. 10 at 4:51 PM

$LUCD Need LCD and people including me will make the buys. I have a ton of cash to deploy ,but would rather pay higher to mitigate risk. Reminder of high interest in views , but we need coverage. Sooner than later.

2 · Reply

mlwtwits Jan. 10 at 3:37 PM

$LUCD How much Longer must we wait? 🥱 I believed in this back during the PAVM run years ago. I still believe.

2 · Reply

Market Cap	163.84M
Revenue (ttm)	4.35M
Net Income (ttm)	-45.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,046.67%
Debt to Equity Ratio	0.86

Volume	277,400
Avg Vol	649,384
Day's Range	N/A - N/A
Shares Out	137.68M
Stochastic %K	76%
Beta	1.22
Analysts	Strong Sell
Price Target	$3.79